Please ensure Javascript is enabled for purposes of website accessibility

Inovio Pharmaceuticals Continues to Sink Lower

By Maxx Chatsko - Mar 19, 2020 at 4:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors might be coming to grips with the long odds facing the company.

What happened

Shares of Inovio Pharmaceuticals (INO 9.52%) tumbled as much as 18% today as investors try to figure out exactly how the business fits in with global efforts to combat the coronavirus pandemic. After becoming one of the faces of early efforts to develop a vaccine, the stock has fallen by more than half since its peak earlier this month. 

It appears investors are coming to grips with the long odds facing the company, which has never successfully developed nor commercialized a drug product. Inovio Pharmaceuticals could still bring a viable SARS-CoV-2 vaccine to market, but it will take another year or so in a best case scenario.

As of 3:45 p.m. EDT, the pharma stock had settled to a 13.2% loss.

A scientist with a dejected look on his face.

Image source: Getty Images.

So what

Inovio Pharmaceuticals hasn't been shy about touting its efforts to develop a SARS-CoV-2 vaccine. Scientists at the company designed a vaccine hours after receiving the viral genome. Of course, designing a vaccine is the easy part. Designing one that works and has been proven safe and effective in clinical trials is the difficult part.

Investors shouldn't forget that clinical trials are still a bottleneck to drug development -- there are limits to how quickly they can be completed. There's also the risk that a moderately effective vaccine triggers an immune response that makes infections worse. And then there's the tidal wave of other companies developing and testing their own vaccines, from fellow development-stage pharma companies such as Moderna to global vaccine leaders such as Sanofi

Now what

Unlike outbreaks of SARS and MERS, which were contained and allowed to fade from memory, the world will probably need a vaccine to protect against COVID-19 in the next few years. That said, it's more likely that scientists discover a drug or combinations of drugs that make cases less severe in the short run, which could make a vaccine a little less urgent. Will Inovio Pharmaceuticals really be one of the companies that finds success? It's possible, but investors have their doubts.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.07 (9.52%) $0.18
Sanofi Stock Quote
Sanofi
SNY
$50.18 (-1.63%) $0.83
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$155.54 (3.73%) $5.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.